Movement Alert｜WuXi Biologics Rises 3.21% in Regular Trading, Aggressive Buyback Program and Sector Rebound Drive Recovery

Market Focus

Jun 12

On June 12, WuXi Biologics rose 3.21% in regular trading, trading at 30.84 HKD/share, with turnover of 358 million HKD. The rebound comes as the company continues its aggressive share repurchase program while the broader Life Sciences Tools & Services sector recovers from last week's sell-off triggered by the US Department of Defense's 1260H list update.

The company repurchased 3.388 million shares on June 11 for approximately 99.82 million HKD, marking the latest in a series of consecutive buybacks. Since early June, cumulative repurchases have exceeded 599 million HKD across eight transactions this year, as part of the broader 400 million USD buyback plan announced earlier. Guotai Junan International recently maintained its Outperform rating with a target price of 54.49 HKD, implying approximately 77% upside, while CICC maintained a 48 HKD target price.

The sector showed broad-based strength, with WuXi XDC up 4.49%, XtalPi up 4.1%, GenScript Biotech up 2.7%, Insilico Medicine up 2.32%, and WuXi AppTec up 2.11%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1135244802"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135244802\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135244802?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 11:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135244802","market":"hk","top_or_hot":-1,"title":"Movement Alert｜WuXi Biologics Rises 3.21% in Regular Trading, Aggressive Buyback Program and Sector Rebound Drive Recovery","media":"Market Focus","content":"<p><p>On June 12, WuXi Biologics rose 3.21% in regular trading, trading at 30.84 HKD/share, with turnover of 358 million HKD. The rebound comes as the company continues its aggressive share repurchase program while the broader Life Sciences Tools & Services sector recovers from last week's sell-off triggered by the US Department of Defense's 1260H list update.</p><p>The company repurchased 3.388 million shares on June 11 for approximately 99.82 million HKD, marking the latest in a series of consecutive buybacks. Since early June, cumulative repurchases have exceeded 599 million HKD across eight transactions this year, as part of the broader 400 million USD buyback plan announced earlier. Guotai Junan International recently maintained its Outperform rating with a target price of 54.49 HKD, implying approximately 77% upside, while CICC maintained a 48 HKD target price.</p><p>The sector showed broad-based strength, with WuXi XDC up 4.49%, XtalPi up 4.1%, GenScript Biotech up 2.7%, Insilico Medicine up 2.32%, and WuXi AppTec up 2.11%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi Biologics Rises 3.21% in Regular Trading, Aggressive Buyback Program and Sector Rebound Drive Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi Biologics Rises 3.21% in Regular Trading, Aggressive Buyback Program and Sector Rebound Drive Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-12 11:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 12, WuXi Biologics rose 3.21% in regular trading, trading at 30.84 HKD/share, with turnover of 358 million HKD. The rebound comes as the company continues its aggressive share repurchase program while the broader Life Sciences Tools & Services sector recovers from last week's sell-off triggered by the US Department of Defense's 1260H list update.</p><p>The company repurchased 3.388 million shares on June 11 for approximately 99.82 million HKD, marking the latest in a series of consecutive buybacks. Since early June, cumulative repurchases have exceeded 599 million HKD across eight transactions this year, as part of the broader 400 million USD buyback plan announced earlier. Guotai Junan International recently maintained its Outperform rating with a target price of 54.49 HKD, implying approximately 77% upside, while CICC maintained a 48 HKD target price.</p><p>The sector showed broad-based strength, with WuXi XDC up 4.49%, XtalPi up 4.1%, GenScript Biotech up 2.7%, Insilico Medicine up 2.32%, and WuXi AppTec up 2.11%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1135244802","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135244802","pubTimestamp":1781235882,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 12, WuXi Biologics rose 3.21% in regular trading, trading at 30.84 HKD/share, with turnover of 358 million HKD. The rebound comes as the company continues its aggressive share repurchase...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"动向提示|药明生物常规交易涨3.21%激进回购计划及板块反弹推动复苏","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On June 12, WuXi Biologics rose 3.21% in regular trading, trading at 30.84 HKD/share, with turnover of 358 million HKD. The rebound comes as the company continues its aggressive share repurchase program while the broader Life Sciences Tools & Services sector recovers from last week's sell-off triggered by the US Department of Defense's 1260H list update.The company repurchased 3.388 million shares on June 11 for approximately 99.82 million HKD, marking the latest in a series of consecutive buybacks. Since early June, cumulative repurchases have exceeded 599 million HKD across eight transactions this year, as part of the broader 400 million USD buyback plan announced earlier. Guotai Junan International recently maintained its Outperform rating with a target price of 54.49 HKD, implying approximately 77% upside, while CICC maintained a 48 HKD target price.The sector showed broad-based strength, with WuXi XDC up 4.49%, XtalPi up 4.1%, GenScript Biotech up 2.7%, Insilico Medicine up 2.32%, and WuXi AppTec up 2.11%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}